[EN] CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME<br/>[FR] 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIQUE CRISTALLIN ET CRISTALLIN LIQUIDE ET SES PROCÉDÉS DE PRÉPARATION
申请人:DURECT CORP
公开号:WO2021133976A1
公开(公告)日:2021-07-01
Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided
本文描述了25HC3S钠的结晶和液晶形式。公开包括25HC3S钠的I、II、III、V、IX、XI和XIII形式及其组合。还公开了所述形式或其组合的药物配方,以及治疗或预防高胆固醇血症、高甘油三酯血症以及与脂肪积累和炎症相关的疾病(例如非酒精性脂肪肝病(NAFLD)、非酒精性脂肪性肝炎(NASH)、酒精性肝炎、急性肾损伤(AKI)、牛皮癣和动脉粥样硬化)的方法也在此公开。还提供了制备25HC3S的方法。